Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

3.660 -0.030 (-0.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
From DiaMedica Therapeutics
Via Business Wire
Carnival Surges Over 12%, Here's 75 Biggest Movers From Friday
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Schenker and USA Truck announced plans to combine and create premier North American transportation... 
Via Benzinga
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
From DiaMedica Therapeutics
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Preview For DiaMedica Therapeutics
DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
DiaMedica Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update May 5, 2022
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Fourth Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
DiaMedica Therapeutics Earnings Preview
DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
DiaMedica Therapeutics Announces Appointment of Dominic Cundari as Chief Commercial Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present Research at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Dr. Kirsten Gruis as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
DiaMedica Therapeutics Announces Closing of $30 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
50 Biggest Movers From Yesterday
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares surged 50% to close at $3.60 on Monday after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 2%; ASLAN Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 0.70% to 35,041.74 while the NASDAQ fell 0.51% to 14,970.85. The S&P also rose, gaining 0.02% to 4,456.20. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
31 Stocks Moving In Monday's Mid-Day Session
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company said its subsidiary, Skypersonic, Inc, won a five-year contract from NASA to... 
Via Benzinga
DiaMedica Therapeutics Announces $30 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.